Bio-Connect

Anti-PD-L1 Antibody [PD01-02]

HA721176
HUABIO
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin, Other Application
Product group Antibodies
TargetCD274
100 ul
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    HUABIO
  • Product Name
    Anti-PD-L1 Antibody [PD01-02]
  • Delivery Days Customer
    2
  • Applications
    Western Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin, Other Application
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    PD01-02
  • Concentration
    0.977 mg/ml
  • Conjugate
    Unconjugated
  • Gene ID29126
  • Target name
    CD274
  • Target description
    CD274 molecule
  • Target synonyms
    ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, hPD-L1, programmed cell death 1 ligand 1, B7 homolog 1, CD274 antigen, PDCD1 ligand 1
  • Host
    Rabbit
  • Isotype
    IgG
  • Protein IDQ9NZQ7
  • Protein Name
    Programmed cell death 1 ligand 1
  • Scientific Description
    PD-L1 (programmed-death ligand 1; CD274), is a transmembrane protein constitutionally expressed on a variety of cell types, including antigen presenting cells (dendritic cells and histiocytes) and some non-lymphoid tissues (heart and lung). Binding of PD-L1 to PD-1 (programmed-death 1; CD279) expressed by activated T-cells, inhibits their function, causing negative feedback control of immunological reactions, thus impeding inflammation and autoimmunity. Tumour cells may express PD-L1, which binds to PD-1 allowing cancer cells to evade the attack of T-cells. Blockade of the PD-1/PD-L1 pathway has now shown useful in therapy of multiple cancer types, causing durable tumour regressions in a substantial proportion of otherwise treatment refractory cases of melanoma, and carcinomas of e.g., lung, kidney, and urinary tract. Patients without tumour PD-L1 expression can also derive benefit from blocking agents (studies across multiple cancer types demonstrate a pooled response rate of 48% in patients with PD-L1-positive tumours compared to 15% in PD-L1-negative tumours). Tonsil and placenta can be used as positive and negative tissue controls. However, tonsil is found to be superior to placenta, as tonsil displayes a range of PD-L1 expression levels. Tonsil displayes the following reaction pattern: No staining reaction in the vast majority of lymphocytes including mantle zone and germinal centre B-cells, no staining reaction in superficial epithelial cells, a weak to moderate, typically punctuated membranous staining reaction of the majority of germinal centre macrophages and finally a moderate to strong staining reaction of the majority of epithelial crypt cells.
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    41116161